Editorial review highlights novel small-molecule agents and therapeutic targets against multidrug-resistant cancers, indicating new pathways to overcome treatment failure.
edge immunotherapy, is only 10%-20% effective, encountering resistance as well in certain patients Thus, MDR appears to be one of the major challenges in cancer treatment, which significantly undermines patients' survival and quality of life The causes of MDR are usually multi-facet Therefore, in the current Research Topic "Novel Small-Molecule Agents in Overcoming Multidrug Resistance in Cancers," we attempted to collect the most-recent progress made in identifying new targets and agents in the treatment of drug-resistant cancers. In total, after being peerreviewed, 20 manuscripts, composed with 13 research articles and seven review articles authored by 187 researchers worldwide, were successfully accepted for publication.
No takes yet. Share an insight, caveat, or question.
Cui et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: